Search results for "Droni"
showing 6 items of 596 documents
K∗(892)0 and φ(1020) production in p-Pb collisions at √sNN = 8.16 TeV
2023
The production of K∗(892)0 and ϕ(1020)resonances has been measured in p-Pb collisions at √sNN = 8.16 TeV using the ALICE detector. Resonances are reconstructed via their hadronic decay channels in the rapidity interval −0.5 8 GeV/c), the RpPb values of all hadrons are consistent with unity within uncertainties. The RpPb of K∗(892)0and ϕ(1020)at √sNN = 8.16 and 5.02 TeV show no significant energy dependence. peerReviewed
Observation of flow angle and flow magnitude fluctuations in Pb-Pb collisions at √sNN = 5.02 TeV at the CERN Large Hadron Collider
2023
This Letter reports on the first measurements of transverse momentum dependent flow angle Ψn and flow magnitude vn fluctuations determined using new four-particle correlators. The measurements are performed for various centralities in Pb–Pb collisions at a center-of-mass energy per nucleon pair of √SNN = 5.02 TeV with ALICE at the CERN Large Hadron Collider. Both flow angle and flow magnitude fluctuations are observed in the presented centrality ranges and are strongest in the most central collisions and for a transverse momentum pT>2GeV/c. Comparison with theoretical models, including iEBE-VISHNU, MUSIC, and AMPT, show that the measurements exhibit unique sensitivities to the initial state…
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis.
2007
Cathepsin K serum levels were determinated in patients with bone metastases from breast cancer or prostate cancer in therapy with zoledronic acid or in patients or in patients with located breast or prostate cancer end in patients with non malignant diseases and in healthy blood. donors (control group). Cathepsin K serum levels were significantly more eleved in healthy subjects or in patients with peimary osteoporosis. Furthermore, the administration of Zoledronic acid to patients with metastatic bome disease from breast or prostate cancer, induced a marked increase of Cathepsin K serum levels.
Analysis of molecular mechanisms and anti-tumoral effects of zoledronic acid in breast cancer cells
2012
Background: Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. Aims: Since breast cancer is one of the primary tumors with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on MCF-7 breast cancer cells treated with l…
Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid
2007
Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also o…
Search for the Decay of the Higgs Boson to Charm Quarks with the ATLAS Experiment
2018
A direct search for the standard model Higgs boson decaying to a pair of charm quarks is presented. Associated production of the Higgs and Z bosons, in the decay mode ZH→ℓ+ℓ−c¯c is studied. A data set with an integrated luminosity of 36.1 fb−1 of pp collisions at √s=13TeV recorded by the ATLAS experiment at the LHC is used. The H→c¯c signature is identified using charm-tagging algorithms. The observed (expected) upper limit on σ(pp→ZH)×B(H→c¯c) is 2.7 (3.9+2.1−1.1) pb at the 95% confidence level for a Higgs boson mass of 125 GeV, while the standard model value is 26 fb.